Boehringer, Eli Lilly get FDA fast track status for Jardiance to treat chronic kidney disease
Boehringer Ingelheim and Eli Lilly have secured fast track status from the US Food and Drug Administration (FDA) for the investigation of Jardiance (empagliflozin) to treat chronic kidney disease.